Last update Aug. 19, 2021


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Synthetic peptide similar to oxytocin, antagonist of human oxytocin receptors that inhibits uterine contractions.
Used as a tocolytic to stop premature labor.
Intravenous administration for a maximum of 48 hours.

At the date of the last update, the authors did not find any published data on its excretion in breast milk.
According to the manufacturer, small amounts of atosiban have been observed to pass from plasma into breast milk during breastfeeding (Accord 2015, EMA 2010).

Its pharmacokinetic data (large volume of distribution, high molecular weight and short half-life) make it unlikely that significant quantities will pass into breast milk.

Its low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.

In review papers and clinical trials with atosiban, no effects on breastfeeding were observed (Lopez 2018, Accord 2015, EMA 2010).


We do not have alternatives for Atosiban.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Atosiban in other languages or writings:

  • أتوسيبان (Arabic)
  • Атозибан (Cyrillic)
  • 阿托西班 (Chinese)
  • アトシバン (Japanese)
  • 1-(3-Mercaptopropionic acid)-2-[3-(p-ethoxyphenyl)-d-alanine]-4-l-threonine-8-l-ornithineoxytocin; [1-(3-Sulfanylpropanoyl),2-(4-O-ethyltyrosine),4-l-threonine-8-l-ornithine]oxytocin (Chemical name)
  • C43H67N11O12S2 (Molecular formula)
  • G02CX01 (ATC Code/s)


Atosiban belongs to this group or family:


Main tradenames from several countries containing Atosiban in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 994 daltons
Protein Binding 46 - 48 %
VD 0.25 - 0.6 l/Kg
pKa 11.28 -
Tmax 1 hours
1.7 ± 0.3 hours


  1. López Gómez L, Marín Gabriel MA, Encinas B, de la Cruz Troca JJ, Rodríguez Marrodán B. Oxytocin Receptor Antagonist (Atosiban) in the Threat of Preterm Birth: Does It Have Any Effect on Breastfeeding in the Term Newborn? Breastfeed Med. 2018 Mar;13(2):123-128. Abstract
  2. Accord Healthcare. Atosiban. Ficha técnica. 2015 Full text (in our servers)
  3. EMA. Atosiban. Drug Summary. 2010 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM